Investment analysts at Stifel Nicolaus raised their target price on shares of Santarus (NASDAQ: SNTS) from $13.00 to $15.00 in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock.
Santarus opened at 13.80 on Tuesday. Santarus has a 52-week low of $4.65 and a 52-week high of $13.80. The stock’s 50-day moving average is currently $12.94. The company has a market cap of $871.7 million and a price-to-earnings ratio of 62.16.
Santarus last issued its quarterly earnings data on Monday, March 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.07. The company had revenue of $70.20 million for the quarter, compared to the consensus estimate of $62.02 million. The company’s quarterly revenue was up 64.8% on a year-over-year basis. Santarus has set its FY13 guidance at $0.92-1.00 EPS. Analysts expect that Santarus will post $0.20 EPS for the current fiscal year.
Separately, analysts at Leerink Swann initiated coverage on shares of Santarus in a research note to investors on Thursday, January 31st. They set an “outperform” rating on the stock.
Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.